Kymera Investor Presentation Deck

Degrading IRAK4: Best Approach to Block IL-1R/TLR driven Inflammation IRAK3 TLRs (TLR 2,4,5,7,8,9) signaling NFkB IL-1R/TLR Pathway IL-1 a/B, IL-18, IL-33, IL-36 Myddosome IKKS MyD88 IRAK4 IRAK 1 IRAK2 TRAF6 c-Jun KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. IL-1R JNK/p38 secreted TNF-a, IFN-Y, IL-1B, IL-6, IL-8, IL-10, IL-12, IL-17, IL-23 Degrader Advantage Inhibitor Scaffolding Role JNK/p38 NFkB IRAK4 Degrader Kinase Role IRF5/7 Clinical Pathway Validation IL-1a/IL-1ß: Rheumatoid Arthritis, CAPS, Hidradenitis Suppurativa IL-1α: Atopic Dermatitis IL-1ß: Gout; CANTOS Outcomes Data in Atherosclerosis and Lung Cancer IL-18: Macrophage Activation Syndrome IL-36: Generalized Pustular Psoriasis, Atopic Dermatitis IRAK4 SMI: Rheumatoid Arthritis Human Genetics Adult humans with IRAK4 Null Mutation are healthy IRAK4 degrader has potential to achieve a broad, well-tolerated anti-inflammatory effect, providing multiple development opportunities in autoimmune inflammatory diseases PAGE 10

View entire presentation